IBDEI136 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18464,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,18464,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,18465,0)
 ;;=C91.40^^79^879^51
 ;;^UTILITY(U,$J,358.3,18465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18465,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18465,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,18465,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,18466,0)
 ;;=C90.00^^79^879^52
 ;;^UTILITY(U,$J,358.3,18466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18466,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,18466,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,18466,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,18467,0)
 ;;=C90.01^^79^879^53
 ;;^UTILITY(U,$J,358.3,18467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18467,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,18467,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,18467,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,18468,0)
 ;;=C91.00^^79^879^54
 ;;^UTILITY(U,$J,358.3,18468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18468,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18468,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,18468,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,18469,0)
 ;;=C91.01^^79^879^55
 ;;^UTILITY(U,$J,358.3,18469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18469,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18469,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,18469,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,18470,0)
 ;;=C91.10^^79^879^56
 ;;^UTILITY(U,$J,358.3,18470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18470,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia B-Cell Type,Not in Remissio
 ;;^UTILITY(U,$J,358.3,18470,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,18470,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,18471,0)
 ;;=C91.11^^79^879^57
 ;;^UTILITY(U,$J,358.3,18471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18471,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,18471,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,18471,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,18472,0)
 ;;=C92.00^^79^879^58
 ;;^UTILITY(U,$J,358.3,18472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18472,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18472,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,18472,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,18473,0)
 ;;=C92.01^^79^879^59
 ;;^UTILITY(U,$J,358.3,18473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18473,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18473,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,18473,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,18474,0)
 ;;=C92.41^^79^879^60
 ;;^UTILITY(U,$J,358.3,18474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18474,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18474,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,18474,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,18475,0)
 ;;=C92.41^^79^879^61
 ;;^UTILITY(U,$J,358.3,18475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18475,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18475,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,18475,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,18476,0)
 ;;=C92.50^^79^879^62
 ;;^UTILITY(U,$J,358.3,18476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18476,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18476,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,18476,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,18477,0)
 ;;=C92.51^^79^879^63
